HER2 status and disparities in luminal breast cancers

National Comprehensive Care Network guidelines for adjuvant treatment of invasive breast cancer are based on HER2 and hormone receptor (HR) status, where HR+ disease encompasses all estrogen receptor (ER)+ and/or progesterone receptor (PR)+ tumors. We sought to explore clinical and demographic diffe...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Med
Egile Nagusiak: Holowatyj, Andreana N., Ruterbusch, Julie J., Ratnam, Manohar, Gorski, David H., Cote, Michele L.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2016
Gaiak:
Cancer Prevention
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4893351/
https://ncbi.nlm.nih.gov/pubmed/27250116
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.757
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak